Summary

for people ages 18-80 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Melvin Heyman

Description

Summary

The study consists of 3 sub-studies, as follows: - Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in subjects with moderately to severely active Crohn's disease (CD) who responded to risankizumab induction treatment in Study M16-006 or Study M15-991 - Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in subjects who responded to induction treatment in Study M16-006 or Study M15-991; - Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in subjects who completed Sub-study 1, Sub-study 2 or the Phase 2, open-label extension study M15-989.

Official Title

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

Keywords

Crohn's Disease risankizumab ABBV-066 BI 655066 Crohn Disease Antibodies, Monoclonal risankizumab IV risankizumab SC Open-label Risankizumab (Sub-Study 3) Double-blind Risankizumab Dose 2 (Sub-Study 1) Maintenance Risankizumab Dose 1 (Sub-Study 2) Double-blind Risankizumab Dose 1 (Sub-Study 1) Maintenance Risankizumab Dose 2 (Sub-Study 2)

Eligibility

You can join if…

Open to people ages 18-80

  • Subjects who have entered and completed Study M16-006 or Study M15-991 or Study M15-989.
  • Subjects have completed the study M16-006 or M15-991 and have achieved clinical response.

You CAN'T join if...

  • Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study .
  • Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of CHO, or had an AE during Studies M16-006, M15-991 or M15-989 that in the Investigator's judgment makes the subject unsuitable for this study.
  • Subject is not in compliance with prior and concomitant medication requirements throughout Studies M16-006, M15-991 or M15-989.
  • Confirmed positive urine pregnancy test at the Final Visit of Study M16-006, Study M15-991 or Study M15-989.
  • Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.

Locations

  • University of California, San /ID# 157127 not yet accepting patients
    San Francisco California 94158 United States
  • Cedars-Sinai Medical Center - West Hollywood /ID# 163839 not yet accepting patients
    West Hollywood California 90048 United States
  • TLC Clinical Research Inc /ID# 212719 accepting new patients
    Beverly Hills California 90211-2091 United States
  • Gastrointestinal Biosciences /ID# 162657 accepting new patients
    Los Angeles California 90067-2001 United States

Lead Scientist

  • Melvin Heyman
    Professor, Pediatrics. Authored (or co-authored) 300 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03105102
Phase
Phase 3
Study Type
Interventional
Last Updated